Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05125016
Title REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Stanford Cancer Center RECRUITING Palo Alto California 94304 United States Details
Norton Cancer Institute RECRUITING Louisville Kentucky 40207 United States Details
University of Maryland, Greenebaum Comprehensive Cancer Center RECRUITING Baltimore Maryland 21201 United States Details
Rutgers Cancer Institute of New Jersey RECRUITING New Brunswick New Jersey 08901 United States Details
Roswell Park Cancer Institute RECRUITING Buffalo New York 14263 United States Details
James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center RECRUITING Columbus Ohio 43210 United States Details
University of Pennsylvania Perelman Center for Advanced Medicine RECRUITING Philadelphia Pennsylvania 19104 United States Details
Thomas Jefferson University, Sidney Kimmel Center, Clinical Research Organization RECRUITING Philadelphia Pennsylvania 19107 United States Details
Fox Chase Cancer Center WITHDRAWN Philadelphia Pennsylvania 19111 United States Details
MD Anderson Cancer Center RECRUITING Houston Texas 77030 United States Details
Froedtert and Medical College of Wisconsin RECRUITING Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field